Physician profile
Michael A Hoffman
NPI 1871589226
$2,766.19
in general payments reported to CMS, 2019-2025
10 companies · $674 in 2025
The $674 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $75.55 · 2021: $274 · 2022: $168 · 2023: $511 · 2024: $677 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.06 |
| Education | $158.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $806.90 | 2023-2025 | Caplyta |
| Abbvie INC. | $761.42 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $471.08 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $286.56 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $136.15 | 2021-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $111.49 | 2024 | |
| Vanda Pharmaceuticals INC. | $102.75 | 2025 | Fanapt |
| Neuronetics, INC. | $58.25 | 2019 | |
| Corium, LLC | $18.92 | 2023 | Azstarys |
| Astellas Pharma US INC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.